New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
09:59 EDTTQNT, TRXC, WBMD, SWKS, SNDK, NCLH, JAZZ, FMI, ADHD, RFMD, MHR, HAFC, CVA, ACOR, PCL, KRO, GBDC, BNFT, ACRXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at Canaccord... Acorda Therapeutics (ACOR) initiated with a Hold at Canaccord... Alcobra (ADHD) initiated with a Buy at Canaccord... Benefitfocus (BNFT) initiated with a Market Perform at William Blair... Cameron (CAM) initiated with a Buy at Gabelli... Covanta (CVA) initiated with an Outperform at Macquarie... Foundation Medicine (FMI) initiated with a Market Perform at William Blair... Golub Capital (GBDC) initiated with an Outperform at Raymond James... Hanmi Financial (HAFC) initiated with an Outperform at Raymond James... Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Canaccord... Kronos Worldwide (KRO) initiated with a Reduce at SunTrust... Magnum Hunter (MHR) initiated with a Hold at Maxim... Norwegian Cruise Line (NCLH) initiated with a Buy at Longbow... Plum Creek Timber (PCL) initiated with an Outperform at RBC Capital... RF Micro Devices (RFMD) initiated with a Market Perform at BMO Capital... SanDisk (SNDK) assumed with an Overweight at Piper Jaffray... Skyworks (SWKS) initiated with a Market Perform at BMO Capital... TransEnterix (TRXC) initiated with a Buy at Sterne Agee... TriQuint (TQNT) initiated with a Market Perform at BMO Capital... WebMD (WBMD) initiated with an Outperform at William Blair.
News For ACRX;ACOR;ADHD;BNFT;CVA;FMI;GBDC;HAFC;JAZZ;KRO;MHR;NCLH;PCL;RFMD;SNDK;SWKS;TRXC;TQNT;WBMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 24, 2015
12:30 EDTADHDOn The Fly: Top stock stories at midday
Subscribe for More Information
10:03 EDTADHDHigh option volume stocks: VNDA SN ADHD UNIS
10:00 EDTADHDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Autoliv (ALV) downgraded to Sell from Neutral at Goldman... Catamaran (CTRX) downgraded to Neutral from Buy at UBS... Citi (C) downgraded to Hold from Buy at Deutsche Bank... Esperion (ESPR) downgraded to Neutral from Outperform at Credit Suisse... Fortinet (FTNT) downgraded to Neutral from Buy at Citi... General Motors (GM) downgraded to Neutral from Buy at Goldman... Goldman Sachs (GS) downgraded to Hold from Buy at Deutsche Bank... IBERIABANK (IBKC) downgraded to Neutral from Outperform at Baird... Independent Bank (INDB) downgraded to Underperform from Neutral at Baird... Inphi (IPHI) downgraded to Market Perform from Outperform at Northland... MoneyGram (MGI) downgraded to Neutral from Outperform at Macquarie... Sensata (ST) downgraded to Hold from Buy at Cross Research... Teradyne (TER) downgraded to Buy from Conviction Buy at Goldman... Alcobra (ADHD) downgraded to Hold from Speculative Buy at WBB Securities.
09:25 EDTADHDAlcobra downgraded to Hold from Speculative Buy at WBB Securities
Subscribe for More Information
09:10 EDTADHDOn The Fly: Pre-market Movers
Subscribe for More Information
07:45 EDTADHDAlcobra to hold a conference call
Subscribe for More Information
07:09 EDTACORAcorda says oral levodopa reduces duration of OFF episodes in PD patients
Subscribe for More Information
06:04 EDTADHDAlcobra's MDX did not meet ADHD endpoint in Phase 2 trial
Subscribe for More Information
June 23, 2015
19:03 EDTADHDOn The Fly: After Hours Movers
UP AFTER PROVIDING GUIDANCE: MeetMe (MEET), up 18.8%. ALSO HIGHER: Nektar Therapeutics (NKTR), up 4.3% after being added to S&P 600... Quidel (QDEL), up 5% after receiving FDA clearance for new Solana molecular system and assay... Vanda Pharmaceuticals (VNDA), up 4.6% after announcing positive results from REPRIEVE study... Netflix (NFLX), up 3.4% after announcing seven-for-one stock split. LOWER: Alcobra (ADHD), down 2.5% after announcing that it will host a conference call and simultaneous webcast presentation to present results from the Phase II clinical trial of MDX... Sysco (SYY), down 2.6% after bid for U.S. foods blocked was blocked by a federal judge... Boeing (BA), down marginally after announcing CEO transition.
17:43 EDTADHDAlcobra to present results from the Phase II clinical trial of MDX
Subscribe for More Information
June 22, 2015
10:00 EDTSNDKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:34 EDTSNDKSanDisk upgraded to Buy from Hold at Summit Research
Subscribe for More Information
June 19, 2015
17:27 EDTMHRRelational Investors lowers stake in Magnum Hunter to 10.51% from 13.2%
15:57 EDTMHRMagnum Hunter spikes after senior bank loan extended
Subscribe for More Information
08:12 EDTSWKSSkyworks price target raised to $125 from $115 at BofA/Merrill
Subscribe for More Information
June 18, 2015
16:37 EDTMHRMagnum Hunter closes on agreement to sell certain Tyler acreage
Subscribe for More Information
08:01 EDTSWKSSkyworks raises quarterly dividend 100% to 26c per share
Subscribe for More Information
June 17, 2015
06:31 EDTHAFCHanmi added to Top Picks List, Discover removed at FBR Capital
Subscribe for More Information
June 16, 2015
08:40 EDTSWKSSkyworks likely to beat consensus but valuation stretched, says Stephens
Subscribe for More Information
07:05 EDTACORAcorda: Patients treated with CVT-301 showed greater motor function vs. placebo
Acorda Therapeutics presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa under development for the episodic treatment of OFF episodes associated with Parkinsonís disease. OFF episodes are characterized by a re-emergence of PD motor symptoms, such as impaired ability to move, muscle stiffness and tremor. The trial showed that patients experiencing an OFF episode, treated with CVT-301, showed significantly greater improvements in motor function than patients treated with inhaled placebo; the difference in improvement was already apparent 10 minutes after dosing and was durable for at least an hour, the longest time point at which patients were measured. These data were presented at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, CA. The Phase 2b trial was a randomized, double blind, placebo-controlled, multicenter study in 86 people with PD for the treatment of OFF episodes. Participants were randomized to self-administer CVT-301 or placebo as an adjunct to oral PD medications. Participants received 35mg of CVT-301 or placebo delivered to the lung in weeks 1 and 2, and 50mg of drug or placebo delivered to the lung in weeks 3 and 4. In-office assessments of the Unified Parkinsonís Disease Rating Scale Part 3 were performed at weeks 1, 2 and 4. The primary endpoint was defined as the mean change from baseline in UPDRS III score after 4 weeks of treatment. UPDRS III is an established scale to monitor PD motor impairment, and is considered a standard in the field. In this study, participants receiving CVT-301 showed a statistically significant and clinically important reduction in average UPDRS III motor score compared to placebo and across all measured time points beginning at 10 and up to 60 minutes post-administration. Both doses of CVT-301 were well tolerated, with no increase relative to placebo in troublesome or non-troublesome dyskinesias during ON periods. There were no serious adverse events reported in the drug group, and the incidence of drug-related adverse events was similar between treatment groups. The most common adverse events were dizziness, headache and cough; there were no adverse events on cardiovascular or lung function. PD patients were able to self-administer treatment while in an OFF state.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use